Many developing countries are considering whether or to what degree they should expand public financing for antiretroviral therapy. In choosing among alternatives, governments need to weigh the future stream of benefits against the costs of each alternative. This symposium presents estimates of future benefits and costs for India, Thailand and South Africa and opens the floor to discussion of the significance of these findings.

A summary of this session is available in the Kaiser Daily HIV/AIDS Report.

View Session ( video ) ( transcript )

Chair:

• Emmanuel Jimenez, director, Human Development Department, East Asia Region, World Bank

Agenda:

India:

• Mead Over, lead economist, Development Research Group, World Bank, Washington

Thailand:

• Ana Revenga, lead economist, Human Development Department, East Asia Region, World Bank, Bangkok
• Wiwat Peerapatanapokin, research associate, East-West Center/Thai Red Cross Collaboration

South Africa:

• Siyabonga Jikwana, acting director, Health Financing and Economics, National Department of Health, Johannesburg

Panelists: 

• Prasada Rao, secretary, Department of Health, Ministry of Health and Family Welfare, India
• Sombat Thanprasertsuk, M.D., Bureau of AIDS, Tuberculosis and Sexually Transmitted Infections, Thailand
• Julian Gold, M.D., director, Albion Centre, Australia
• Paul Toh, UNAIDS, Bangkok
• Fadia Saadah, Health Sector Manager for East Asia, World Bank

• Consult our Frequently Asked Questions or How to View.
• Contact us by email with any comments, problems, suggestions.
• Call the kaisernetwork.org Help Desk at 202-347-5270.